Modulation of Gut Barrier Functions in Ulcerative Colitis by Hyaluronic Acid System.
HA
HA systems
dextran sodium sulfate (DSS)-induced
inflammatory diseases
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
24
07
2021
pubmed:
12
11
2021
medline:
22
3
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
The active stages of intestinal inflammation and the pathogenesis of ulcerative colitis are associated with superficial mucosal damage and intermittent wounding that leads to epithelial barrier defects and increased permeability. The standard therapeutic interventions for colitis have focused mainly on maintaining the remission levels of the disease. Nonetheless, such treatment strategies (using anti-inflammatory, immunomodulatory agents) do not address colitis' root cause, especially the mucosal damage and dysregulated intestinal barrier functions. Restoration of barrier functionality by mucosal healing or physical barrier protecting strategies shall be considered as an initial event in the disease suppression and progression. Herein, a biphasic hyaluronan (HA) enema suspension, naïve-HA systems that protect the dysregulated gut epithelium by decreasing the inflammation, permeability, and helping in maintaining the epithelial barrier integrity in the dextran sodium sulfate-induced colitis mice model is reported. Furthermore, HA-based system modulates intestinal epithelial junctional proteins and regulatory signaling pathways, resulting in attenuation of inflammation and mucosal protection. The results suggest that HA-based system can be delivered as an enema to act as a barrier protecting system for managing distal colonic inflammatory diseases, including colitis.
Identifiants
pubmed: 34761543
doi: 10.1002/advs.202103189
pmc: PMC8811821
doi:
Substances chimiques
Adjuvants, Immunologic
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2103189Subventions
Organisme : NCI NIH HHS
ID : R21 CA216090
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM125504
Pays : United States
Organisme : European Union's Horizon 2020-The EU Framework Programme for Research and Innovation
ID : 646142
Organisme : NIH/NIGMS CoBRE
ID : P20GM125504-01
Organisme : NCI NIH HHS
ID : R21 CA191683
Pays : United States
Organisme : NIH/NCI
ID : R21CA216090
Organisme : Science Foundation Ireland (SFI) and is co-funded by European Regional Development Fund (ERDF)
ID : 13/RC/2073_P2
Organisme : NIH/NCI
ID : CA191683
Informations de copyright
© 2021 The Authors. Advanced Science published by Wiley-VCH GmbH.
Références
Inflamm Bowel Dis. 2010 Jan;16(1):112-24
pubmed: 19653289
J Clin Invest. 1989 Feb;83(2):724-7
pubmed: 2492310
Lancet. 1995 May 13;345(8959):1205-9
pubmed: 7537840
Curr Opin Pediatr. 2016 Oct;28(5):620-5
pubmed: 27583410
World J Gastroenterol. 2012 Jul 28;18(28):3635-61
pubmed: 22851857
Theranostics. 2016 Sep 25;6(12):2250-2266
pubmed: 27924161
Nat Mater. 2020 Jan;19(1):118-126
pubmed: 31427744
Int J Pharm. 2006 Jun 19;316(1-2):138-43
pubmed: 16675176
Inflamm Regen. 2018 Apr 02;38:5
pubmed: 29619131
Front Immunol. 2019 May 20;10:1094
pubmed: 31164887
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Annu Rev Physiol. 2003;65:261-311
pubmed: 12518001
Nat Commun. 2019 Jan 9;10(1):89
pubmed: 30626868
Pharm Res. 2021 Mar;38(3):523-530
pubmed: 33723795
FASEB J. 2000 Sep;14(12):1749-53
pubmed: 10973924
Clin Exp Immunol. 2005 Nov;142(2):260-7
pubmed: 16232212
Crit Care Med. 2003 Aug;31(8 Suppl):S532-7
pubmed: 12907883
World J Gastroenterol. 2008 Jan 21;14(3):348-53
pubmed: 18200658
Histochem Cell Biol. 2008 Aug;130(2):281-97
pubmed: 18597105
J Nanobiotechnology. 2021 Jan 27;19(1):32
pubmed: 33499885
Hum Vaccin Immunother. 2018;14(11):2597-2611
pubmed: 29624476
Mil Med Res. 2017 Apr 27;4:14
pubmed: 28465831
AAPS PharmSciTech. 2010 Jun;11(2):497-508
pubmed: 20333490
Am J Gastroenterol. 2015 Jan;110(1):114-26
pubmed: 25488896
Nature. 2019 Mar;567(7746):49-55
pubmed: 30814735
Biomaterials. 2003 Nov;24(25):4655-61
pubmed: 12951008
Mol Ther. 2017 Jul 5;25(7):1628-1640
pubmed: 28143741
Lancet. 2012 Nov 3;380(9853):1606-19
pubmed: 22914296
Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):585-95
pubmed: 23835489
Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):167-82
pubmed: 20227030
Matrix Biol. 2018 Mar;66:93-109
pubmed: 28978412
Front Immunol. 2019 May 14;10:1070
pubmed: 31139192
World J Gastroenterol. 2006 Aug 14;12(30):4819-31
pubmed: 16937463
Nat Rev Drug Discov. 2006 Dec;5(12):993-6
pubmed: 17139284
Am J Gastroenterol. 2011 Apr;106(4):685-98
pubmed: 21427713
Histopathology. 1998 Apr;32(4):317-21
pubmed: 9602327
Ann N Y Acad Sci. 2009 May;1165:294-300
pubmed: 19538319
Am J Pathol. 2003 Jul;163(1):121-33
pubmed: 12819017
Intest Res. 2015 Jan;13(1):95-6
pubmed: 25691850
J Control Release. 2021 Aug 10;336:598-620
pubmed: 34237401
N Engl J Med. 1989 Feb 9;320(6):365-76
pubmed: 2536474
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4557-76
pubmed: 25197329
Nanomaterials (Basel). 2019 Sep 02;9(9):
pubmed: 31480704
J Biol Chem. 1994 May 6;269(18):13289-95
pubmed: 8175759
Gut. 2012 Jun;61(6):918-32
pubmed: 22115827
Adv Drug Deliv Rev. 2019 Jun;146:248-266
pubmed: 29966684
World J Gastroenterol. 2016 Mar 21;22(11):3117-26
pubmed: 27003989
J Immunol. 2007 Apr 1;178(7):4641-9
pubmed: 17372023
Gut. 1991 Jul;32(7):760-2
pubmed: 1713183
FEBS J. 2016 Jul;283(14):2720-30
pubmed: 27250564
Cell Mol Life Sci. 2013 Feb;70(4):631-59
pubmed: 22782113
Gastroenterology. 2011 May;140(6):1827-1837.e2
pubmed: 21530749
Adv Sci (Weinh). 2022 Feb;9(4):e2103189
pubmed: 34761543
Mayo Clin Proc. 2019 Jan;94(1):155-165
pubmed: 30611442